ENaC-mediated sodium absorption and CFTR-mediated chloride secretion contribute to the measured epithelial voltage. Blocking ENaC with amiloride tests the sodium-absorptive component, while chloride-free solutions or agonist-containing solutions probe chloride transport, particularly CFTR-linked activity. Comparing voltage responses across these conditions helps separate channel contributions rather than relying on a single baseline reading.
These interventions act as functional challenges for distinct ion-transport pathways. Amiloride reduces the contribution from epithelial sodium absorption, whereas chloride-free or agonist-containing solutions reveal changes associated with chloride secretion. The resulting voltage shifts provide pharmacological evidence about channel activity and can indicate whether a transport defect responds to a specific experimental condition.
Nasal Potential Difference provides a functional readout of epithelial ion transport in living tissue. In cystic fibrosis-related channel dysfunction, the response pattern can reflect impaired CFTR-associated chloride secretion and altered sodium transport. This complements molecular measurements by showing how channel activity behaves at the epithelial level, which is relevant when assessing pharmacological correction.
The procedure places an electrode in contact with the nasal mucosa and a reference electrode on reference tissue. The nasal surface is then perfused with defined solutions while voltage is recorded. Researchers compare the signal during baseline conditions and after selected interventions, such as amiloride, chloride-free solutions, or agonist-containing solutions.
Reliable measurements require electrodes that contact the nasal mucosa and reference tissue, together with defined solutions for surface perfusion. The composition of those solutions matters because it determines whether sodium absorption or chloride secretion is being challenged. Recording voltage across these controlled conditions allows responses to be linked to specific epithelial transport processes.
Researchers use Nasal Potential Difference to characterize cystic fibrosis-related channel dysfunction and to evaluate whether investigational drugs restore CFTR activity. The assay can serve as a functional outcome alongside molecular or clinical measures. Its value is greatest when treatment-related voltage changes are interpreted under defined pharmacological and solution conditions that probe ion transport.